Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45506 | 0.85 | MAPT (0.68) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL9284192 | 0.85 | MAPT (0.68) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL8871046 | 0.84 | MAPT (0.67) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL28678208 | 0.83 | MAPT (1.00) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL9871380 | 0.81 | MAPT (0.59) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL8871380 | 0.80 | SMN1; SMN2 (0.65) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL8886917 | 0.80 | MAPT (0.61) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL111242 | 0.80 | LMNA (0.65) | MAPTSMN1; SMN2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL23195619 | 0.80 | MAPT (0.48) | MAPTSMN1; SMN2NPC1RAB9AL3MBTL1 | |
| SCHEMBL28989046 | 0.79 | RAB9A (0.59) | MAPTSMN1; SMN2NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182031-A1 | Reduction of Hair Growth | THE GILLETTE COMPANY, A DELAWARE CORPORATION | 2009-07-16 | — | — | US | claimed |
| EP-1750653-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORSFOR THE REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2007-02-14 | — | — | EP | claimed |
| US-20050249685-A1 | topical applying heat shock protein inhibitors | GILLETTE COMPANY, THE | 2005-11-10 | — | — | US | claimed |
| WO-2005105023-A1 | USE OF HEAT SHOCK PROTEIN INHIBITORSFOR THE REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2005-11-10 | — | — | WO | claimed |
| US-20090182031-A1 | Reduction of Hair Growth | THE GILLETTE COMPANY, A DELAWARE CORPORATION | 2009-07-16 | — | — | US | disclosed |
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | disclosed |
| CN-1946372-A | Use of heat shock protein inhibitors for the reduction of hair growth | GILLETTE CO (US) | 2007-04-11 | — | — | CN | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20060134048-A1 | Reduction of hair growth | GILLETTE COMPANY, THE | 2006-06-22 | — | — | US | disclosed |
| US-20050249685-A1 | topical applying heat shock protein inhibitors | GILLETTE COMPANY, THE | 2005-11-10 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| EP-0086750-A2 | Use of quinoline derivatives in the protection of crop plants | CIBA-GEIGY AG (CH) | 1983-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | MAPT 3557/4885SMN1; SMN2 3554/4885NPC1 122/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | MAPT 3557/4885SMN1; SMN2 3554/4885NPC1 122/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | MAPT 3349/4885SMN1; SMN2 3041/4885NPC1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.